AZN-Aplimmune: Interesting buy, probably would turn out to be one of AZN's better buy. One promising IPO on my watch list gets crossed out - why not IPO in this case? It might also be a sign AZN is serious about NOT doing any large acquisition.
We hadn't heard much except earlier in March this year from partner GSK on AMP224, a fusion protein that blocks the interaction between PD1 and B7-H1.
Market Data 
Markets 
AI
